Jaber and colleagues 1 report the results of a thoughtfully designed trial examining sodium bicarbonate administration to critically ill adults with acidaemia. We congratulate the authors on this accomplishment and pose two questions.
First, the composite primary outcome chosen by the authors-28-day mortality or an organ failure at day 7-has important limitations. Components of the outcome are assessed at differing timepoints, dysfunction in organ systems mechanistically unrelated to the intervention are included in the composite (eg, haematological dysfunction), and the outcome's relevance to patients is unclear. For phase 3 clinical trials involving acute kidney injury, a National Institute of Diabetes and Digestive and Kidney Diseases work group has recommended as a patient-centred outcome the use of major adverse kidney eventsthe composite of death, new receipt of renal-replacement therapy, or persistent renal dysfunction (defined by plasma creatinine values or glomerular filtration rate).
2,3 Can the authors report what proportion of patients in each study group experienced a major adverse kidney event by 28 days (understanding that the data might be censored at hospital discharge)?
Second, one contributor to acidaemia among critically ill adults is receipt of 0·9% sodium chloride. What volume of intravenous fluid did patients receive before enrolment, and what proportion of that fluid was 0·9% sodium chloride? If bicarbonate administration in the trial was, in part, correcting salineinduced hyperchloremic metabolic acidosis, preferential use of balanced crystalloids for initial resuscitation might diminish the need for, and effect of, subsequent bicarbonate therapy. 4 We declare no competing interests. bicarbonate also might have spared saline use and reduced chlorine intake. These two effects would widen the difference in sodium and chlorine concentrations and increase both pH and bicarbonate, which were two of the three indications for dialysis. These criteria were also used more commonly to assess the need for dialysis in the control group than they were in the treatment group and drove the difference in dialysis use (table S8 of the Article appendix).
Ryan
1 Yet, there is no evidence that treating a low pH alters haemodynamics. The use of the sodium bicarbonate solution probably calmed the clinicians because they did not feel that dialysis was necessary. Instead of a reflex dialysis response to acidaemia, what was needed was an understanding of the mechanism and treatment of the acidosis, which would have been a lot cheaper.
We declare no competing interests. 28 days became statistically significant (hazard ratio 0·727, 95% CI 0·54-0·98, p=0·035). Because this study was, apparently, the first randomised controlled trial on this treatment, a meta-analysis cannot be done. Therefore, we need larger trials to clearly identify the effect (or lack of it) of sodium bicarbonate in patients with severe metabolic acidaemia.
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I declare no competing interests. Even though the primary outcome was inconclusive, the encouraging results of the BICAR-ICU study by Jaber and colleagues 1 on the renal secondary outcomes provide some interesting arguments in the debate about the fluids content used in intensive care.
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The beneficial effect of bicarbonate is notably explained by the authors by a decrease in the need for vasopressors. However, we think that the effect could also be linked, in the intervention group, to a lower chloride load with beneficial effects on renal dysfunction. Some experimental studies 2 indeed suggest an association between the chloride input and kidney injuries, in particular through a vasoconstriction of afferent arterioles, causing a decrease in the renal blood flow velocity and pro-inflammatory effects. These observations have also been noted in clinical studies, 3, 4 with, in the study by Shaw and colleagues, 4 a positive effect on mortality.
In the study by Jaber and colleagues, 
